Denali Therapeutics Inc. (NASDAQ:DNLI) Receives $38.90 Average PT from Brokerages

Denali Therapeutics Inc. (NASDAQ:DNLI - Get Free Report) has received a consensus rating of "Moderate Buy" from the eleven analysts that are presently covering the stock, Marketbeat.com reports. Two research analysts have rated the stock with a hold recommendation and nine have given a buy recommendation to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $40.40.

A number of research analysts have recently issued reports on the company. Bank of America lifted their price target on Denali Therapeutics from $25.00 to $29.00 and gave the company a "buy" rating in a report on Wednesday, September 4th. JPMorgan Chase & Co. cut their target price on Denali Therapeutics from $29.00 to $28.00 and set an "overweight" rating on the stock in a research note on Friday, October 11th. HC Wainwright reissued a "buy" rating and set a $90.00 price target on shares of Denali Therapeutics in a research report on Thursday, November 7th. Raymond James restated a "market perform" rating on shares of Denali Therapeutics in a report on Thursday, October 10th. Finally, Jefferies Financial Group boosted their price objective on shares of Denali Therapeutics from $40.00 to $45.00 and gave the stock a "buy" rating in a research note on Friday, November 1st.

Denali Therapeutics Stock Up 1.4 %

NASDAQ:DNLI traded up $0.32 during mid-day trading on Monday, reaching $23.29. The company's stock had a trading volume of 1,000,394 shares, compared to its average volume of 1,050,320. Denali Therapeutics has a 1 year low of $14.56 and a 1 year high of $33.33. The stock has a fifty day moving average of $26.21 and a 200-day moving average of $24.88. The firm has a market capitalization of $3.35 billion, a PE ratio of -8.44 and a beta of 1.35.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.63) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.03). During the same period in the previous year, the firm earned ($0.72) EPS. On average, analysts expect that Denali Therapeutics will post -2.71 earnings per share for the current year.

Insider Activity

In other Denali Therapeutics news, insider Alexander O. Schuth sold 15,558 shares of the company's stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $29.91, for a total transaction of $465,339.78. Following the completion of the transaction, the insider now directly owns 178,066 shares in the company, valued at approximately $5,325,954.06. This represents a 8.04 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Vicki L. Sato sold 1,020 shares of Denali Therapeutics stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $30.00, for a total transaction of $30,600.00. Following the completion of the sale, the director now owns 111,056 shares in the company, valued at approximately $3,331,680. This trade represents a 0.91 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 86,578 shares of company stock worth $2,474,440 in the last ninety days. Company insiders own 7.90% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of DNLI. Franklin Resources Inc. increased its stake in Denali Therapeutics by 3.8% during the 3rd quarter. Franklin Resources Inc. now owns 80,041 shares of the company's stock worth $2,148,000 after buying an additional 2,901 shares in the last quarter. Barclays PLC boosted its stake in shares of Denali Therapeutics by 101.4% in the third quarter. Barclays PLC now owns 255,883 shares of the company's stock worth $7,454,000 after acquiring an additional 128,823 shares during the last quarter. Nomura Asset Management Co. Ltd. purchased a new stake in shares of Denali Therapeutics during the third quarter worth approximately $1,894,000. Pier Capital LLC increased its position in shares of Denali Therapeutics by 1.6% during the third quarter. Pier Capital LLC now owns 168,082 shares of the company's stock worth $4,896,000 after purchasing an additional 2,596 shares in the last quarter. Finally, Wellington Management Group LLP raised its stake in Denali Therapeutics by 9.2% in the 3rd quarter. Wellington Management Group LLP now owns 10,727,450 shares of the company's stock valued at $312,491,000 after purchasing an additional 903,683 shares during the last quarter. Institutional investors and hedge funds own 92.92% of the company's stock.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.